Rabbit anti-Human CD262/DR5/TRAILR2 Monoclonal Antibody for Flow Cytometry - O14763

Core Product Specifications and Parameters

Biological Background: CD262/DR5/TRAILR2 Function and Localization

• CD262/DR5/TRAILR2, encoded by the TNFRSF10B gene, is a member of the tumor necrosis factor receptor superfamily. It is also known as Death receptor 5 (DR5) and TRAIL receptor 2 (TRAIL-R2), serving as a receptor for the cytotoxic ligand TNFSF10/TRAIL. Related references: PMID:10549288
• Upon TRAIL binding, the receptor recruits the adapter molecule FADD and caspase-8, forming the death-inducing signaling complex (DISC). This triggers caspase-8 proteolytic activation and a caspase cascade leading to apoptosis. DR5 also promotes NF-kappa-B activation and is essential for ER stress-induced apoptosis.
• The receptor is widely expressed in adult and fetal tissues, with very high levels in tumor cell lines (e.g., HeLaS3, K-562, HL-60) and organs such as heart, liver, pancreas, spleen, thymus, prostate, ovary, and uterus. It is not detectable in brain.
• Subcellularly, CD262/DR5/TRAILR2 is a transmembrane protein (membrane-bound), with potential soluble isoforms generated by alternative splicing or ectodomain shedding.
• Post-translational modifications include glycosylation and disulfide bond formation, contributing to proper folding and ligand interaction. The protein also features a signal peptide, extracellular cysteine-rich repeats, a transmembrane helix, and a cytoplasmic death domain.
• UniProt keywords highlight its roles in apoptosis, alternative splicing, and its classification as a receptor with proteomics identification and 3D-structure determination.

Experimental Guidance and Technical Tips

• The immunogen used to generate this antibody corresponds to amino acids 56-182 of human CD262/DR5/TRAILR2, which maps to the extracellular ligand-binding domain. This design favors recognition of the native receptor on the cell surface.
• This antibody is provided as an conjugate, enabling direct detection in flow cytometry without the need for a secondary antibody. Consider titrating the antibody to determine the optimal concentration for your specific cell type.
• The protein is reported to have multiple molecular weight forms (12kDa/45kDa/47kDa), possibly reflecting alternative splicing, glycosylation, or cleavage products. Be aware that band patterns in western blot may vary; however, this product is recommended for FC.
• For fixation and permeabilization protocols in flow cytometry, validate that the epitope (extracellular domain) remains accessible after treatment. Live-cell staining is typically recommended for surface receptors.
• As DR5 is highly expressed in many tumor cell lines, positive controls such as HeLaS3 or K-562 are suggested, while brain-derived cells may serve as negative controls.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, laboratories, and research institutes a comprehensive one-stop platform for IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-CD262/DR5/TRAILR2 antibody supports apoptosis and oncology research, and CamelBio can further supply validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and rare-target raw-material sourcing tailored to your diagnostic development needs. Partner with CamelBio to streamline your procurement and accelerate your project timelines with reliable, high-quality reagents.